- /
- Supported exchanges
- / US
- / DBVTF.PINK
DBV Technologies S.A (DBVTF PINK) stock market data APIs
DBV Technologies S.A Financial Data Overview
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get DBV Technologies S.A data using free add-ons & libraries
Get DBV Technologies S.A Fundamental Data
DBV Technologies S.A Fundamental data includes:
- Net Revenue: 5 036 K
- EBITDA: -174 762 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-07-29
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
DBV Technologies S.A News
New
H.C Wainwright and Citizens Raise PT on DBV Technologies (DBVT) Following Phase 3 VITESSE Trial Result
With strong 1-year returns and upside potential, DBV Technologies S.A. (NASDAQ:DBVT) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.H.C Wainwright and Citizens R...
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results
DBV Technologies S.A. Montrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studiesand Reports Second Quarterand Half-Year 2023 Fi...
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update
DBV Technologies S.A. Montrouge, France, July 25, 2023 DBV Technologies to ReportFirst Half 2023 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023
DBV Technologies S.A. Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (Article 223-16 of the General Regulations of the...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.